Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | THRB | P10828 | 1/20 | 0.37 |
| ▸ | GRM5 | P41594 | 3/20 | 0.37 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.37 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.37 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.36 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.36 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23406490 | 1.00 | HSD11B1 (0.41) | HSD11B1HSD17B10KDM4EMAPTTHRB | |
| SCHEMBL5938275 | 1.00 | HSD11B1 (0.41) | HSD11B1HSD17B10KDM4EMAPTTHRB | |
| SCHEMBL1691937 | 0.93 | HSD11B1 (0.40) | HSD11B1HSD17B10CHRM2CHRM1CHRM3 | |
| SCHEMBL1691897 | 0.93 | HSD11B1 (0.40) | HSD11B1HSD17B10CHRM2CHRM1CHRM3 | |
| SCHEMBL5937784 | 0.91 | HSD11B1 (0.48) | HSD11B1HSD17B10 | |
| SCHEMBL30959549 | 0.88 | NPC1 (0.40) | HSD17B10KDM4EMAPTTHRBGRM5 | |
| SCHEMBL5938471 | 0.88 | NPC1 (0.40) | HSD17B10KDM4EMAPTTHRBGRM5 | |
| SCHEMBL15245630 | 0.87 | HSD11B1 (0.42) | HSD11B1HSD17B10HPGD | |
| SCHEMBL5939603 | 0.86 | CHRM2 (0.41) | HSD11B1HSD17B10KDM4EMAPTTHRB | |
| SCHEMBL5938430 | 0.85 | HSD11B1 (0.46) | HSD11B1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3810615-B1 | ARGINASE INHIBITORS AND METHODS OF USE | MERCK SHARP & DOHME LLC (US) | 2026-01-28 | — | — | EP | disclosed |
| US-11274111-B2 | Arginase inhibitors and methods of use | MERCK SHARP & DOHME CORP. (US) | 2022-03-15 | — | — | US | disclosed |
| US-20210163505-A1 | ARGINASE INHIBITORS AND METHODS OF USE | MERCK SHARP & DOHME CORP. (US) | 2021-06-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210163505-A1 | ARGINASE INHIBITORS AND METHODS OF USE | ARG1, ARG2, PRMT1 | HSD11B1 403/4885HSD17B10 1343/4885KDM4E 3146/4885 |
| US-11274111-B2 | Arginase inhibitors and methods of use | ARG1, ARG2, PRMT1 | HSD11B1 403/4885HSD17B10 1343/4885KDM4E 3146/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.